Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
Neurogenic disorders are conditions associated with the central nervous system and affect millions of individuals. They occur when certain nerves become hyper-sensitized due to distress, infection, inflammation or tissue injury; this sensitization can lead to chronic and debilitating symptoms.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?